[18F]AlF-NOTA-octreotide as tracer for somatostatin receptor PET/CT: Retrospective analysis of the clinical use in 288 neuroendocrine tumour patients

#4310

Introduction: [18F]AlF-NOTA-octreotide has emerged as a reliable tracer for somatostatin receptor (SSTR) PET/CT in patients with neuroendocrine neoplasms (NENs). Although effective and logistically advantageous, there remains limited data on its routine clinical application, particularly for specific NEN subtypes (e.g. NET G3).

Aim(s): This study aims to assess the real-world clinical use of [18F]AlF-NOTA-octreotide PET/CT, with an emphasis on uptake characteristics and referral patterns at our institution.

Materials and methods: A retrospective analysis was conducted on all patients referred for SSTR PET/CT at University Hospitals Leuven between March 1, 2023, and January 18, 2024. Relevant clinical and demographic data, along with procedural details, were collected. PET/CT imaging data was analysed to quantify uptake parameters.

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Dekervel J, Cleeren F, Goffin K, Dooms C,

Keywords: [18F]AlF-NOTA-octreotide, routine clinical use, neuroendocrine tumour, somatostatin receptor, PET/CT imaging,